Adenotonsillectomy fails to cure pediatric obstructive sleep apnea in 20-75% of children depending on comorbidities, yet no standard post-surgical screening protocol exists

Adenotonsillectomy (AT) is the first-line surgical treatment for pediatric obstructive sleep apnea, performed on approximately 500,000 U.S. children annually, yet residual OSA persists in 13-29% of otherwise healthy children and in over 70% of children with Down syndrome, obesity, or craniofacial abnormalities -- and most children never receive a follow-up polysomnography to detect persistent disease. Why it matters: parents and pediatricians assume the surgery is curative and do not pursue post-operative sleep testing, so children with residual OSA continue experiencing intermittent hypoxia during critical neurodevelopmental windows, so these children develop behavioral problems, attention deficits, and poor academic performance that are attributed to ADHD or learning disabilities rather than ongoing sleep-disordered breathing, so they are placed on stimulant medications that do not address the root cause, so by adolescence they may develop cardiovascular sequelae including pulmonary hypertension and right heart strain from years of untreated obstruction. The structural root cause is that the American Academy of Pediatrics' 2012 guidelines recommend post-AT polysomnography for high-risk children but do not mandate it, insurance companies rarely cover a follow-up sleep study without documented clinical suspicion of persistent disease, and the pediatric sleep medicine workforce is even smaller than the adult one -- with only approximately 300 board-certified pediatric sleep specialists in the U.S. for 73 million children.